Liraglutide weight loss diabetes
Victoza causes patients to feel fuller for a longer time. Victoza (liraglutide) is an injectable medication used in combination with diet and exercise to reduce blood sugar in patients with type II diabetes mellitus. Its effects are on the gut and the brain, where several GLP-1 receptors are located. All patients received standardized counseling on lifestyle modification approximately monthly (see the Supplementary Appendix ). 1 kg (Orlistat). Victoza is not recommended as a first line therapy for type II diabetes and should not be given to patients with type I diabetes, or diabetic ketoacidosis. 8 mg, 2. Average weight loss with Victoza 3 mg per day was 7. Weight Loss in Victoza Obesity Study (SCALE Study). There is evidence that weight loss occurs in obese patients who are taking Victoza. However, it is currently not approved for weight loss or management of obesity. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3. Assessed the effects of Victoza on weight loss at doses up to 3 mg per day in conjunction with a low calorie diet and exercise in 564 obese patients for 20 weeks. Victoza study in weight management in non-diabetic obese patients. 4 mg, or 3 mg) administered once daily in comparison to placebo and Orlistat 120 mg three times daily orally. 2 kg (5-10% weight reduction) compared to 2.
Abstract Background Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Media in This Article QUICK TAKE VIDEO SUMMARY The SCALE Trial Figure 1 Liraglutide and Body Weight. The sponsor, Novo Nordisk, planned and performed the statistical analyses, provided editorial and writing assistance, and provided the trial drugs. 2 mg, 1. More than 50% of patients treated with Victoza achieved the target of 5-10% weight reduction. Details of the eligibility and exclusion criteria are provided in the Supplementary Appendix. Figure 2 Liraglutide and Glucose Levels during Oral Glucose-Tolerance Test and Glycemic Status. All the authors were involved in the design or conduct of the study and the preparation of the manuscript, including the decision to submit it for publication, and all attest to the accuracy and completeness of data and the data analyses. Key exclusion criteria were type 1 or 2 diabetes, the use of medications that cause clinically significant weight gain or loss, previous bariatric surgery, a history of pancreatitis, a history of major depressive or other severe psychiatric disorders, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. 8 kg (placebo) and 4. It suppresses appetite, decreases the absorption of sugar from the gut, and delays movement of food through the gut. Patients exploring the use of Victoza purely for weight loss should fully understand the risks and benefits of Victoza. Methods Study Overview We conducted the study from June 1, 2011, through March 18, 2013, at 191 sites in 27 countries in Europe, North America, South America, Asia, Africa, and Australia. 0 mg, injected subcutaneously. Study Design and Treatments Randomization was performed with the use of a telephone or Web-based system provided by the sponsor. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. Patients were randomly assigned to one of four Victoza doses (1. By acting like human GLP-1 hormone (incretin hormone), it stimulates insulin secretion by the pancreas, slows the absorption of sugar from the gut and reduces appetite by delaying movement of food through the gut.
